Novel germline JAK2 R715T mutation causing PV ‐like erythrocytosis in 3 generations. Amelioration by Ropeg‐Interferon
American Journal of Hematology · 2024
DOI: 10.1002/ajh.27311 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Jihyun Song und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Germ-Line Mutation, Janus Kinase 2, Polycythemia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grantová Agentura České Republiky, Next Generation EU, Ludwig Institute for Cancer Research.
Abstract (Originalsprache)
Polycythemia vera (PV) is a clonal disorder arising from the acquired somatic mutations of the JAK2 gene, including JAK2 V617F or several others in exon 12. A 38‐year‐old female had a stroke at age 32 and found to have elevated hemoglobin, normal leukocytes, normal platelets, and tested negative for JAK2 V617F and exon 12 mutations. Next generation sequencing revealed a novel mutation: JAK2 R715T in the pseudokinase domain (JH2) at 47.5%. Its presence in her nail DNA confirmed a germline origin. Her mother and her son similarly had erythrocytosis and a JAK2 R715T mutation. Computer modeling indicated gain‐of‐function JAK2 activity. The propositus and her mother had polyclonal myelopoiesis, ruling out another somatic mutation‐derived clonal hematopoiesis. Some erythroid progenitors of all three generations grew without erythropoietin, a hallmark of PV. The in vitro reporter assay confirmed increased activity of the JAK2 R715T kinase. Similar to PV, the JAK2 R715T native cells have increased STAT5 phosphorylation, augmented transcripts of prothrombotic and inflammatory genes, and decreased KLF2 transcripts. The propositus was not controlled by hydroxyurea, and JAK2 inhibitors were not tolerated; however, Ropeginterferon‐alfa‐2b (Ropeg‐IFN‐α) induced a remission. Ropeg‐IFN‐α treatment also reduced JAK2 activity in the propositus, her mother and JAK2 V617F PV subjects. We report dominantly inherited erythrocytosis secondary to a novel germline JAK2 R715T gain‐of‐function mutation with many but not all comparable molecular features to JAK2 V617F PV. We also document a previously unreported inhibitory mechanism of JAK2 signaling by Ropeg‐IFN‐α.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
- Department of Cell and Developmental Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
- Ludwig Institute for Cancer Research, Brussels, Belgium.
- de Duve Institute, Brussels, Belgium.
- Division of Hematology-Oncology, Department of Pediatrics, University of Utah and Primary Children's Hospital, Salt Lake City, Utah, USA.
- Nuffield Department of Medicine, Oxford University, Oxford, UK.
ORCID-Profile: Jihyun Song, Lucie Lanikova, Soo Jin Kim, Nicolas Papadopoulos, Jessica Meznarich, Stefan N Constantinescu, Brynn Parsegov, Josef T Prchal
Förderung
- Grantová Agentura České Republiky
- Next Generation EU
- Ludwig Institute for Cancer Research
- Projet de recherche FNRS
- MPN Research Foundation
- Fonds De La Recherche Scientifique - FNRS
- Walloon excellence in life sciences and biotechnology
- Czech Health Research Council
Zitieren
APA
Song, J., Lanikova, L., Kim, S. J., Papadopoulos, N., Meznarich, J., Constantinescu, S. N., Parsegov, B., Prchal, J. F., & Prchal, J. T. (2024). Novel germline JAK2 R715T mutation causing PV ‐like erythrocytosis in 3 generations. Amelioration by Ropeg‐Interferon. American Journal of Hematology. https://doi.org/10.1002/ajh.27311
Vancouver
Song J, Lanikova L, Kim SJ, Papadopoulos N, Meznarich J, Constantinescu SN, et al. Novel germline JAK2 R715T mutation causing PV ‐like erythrocytosis in 3 generations. Amelioration by Ropeg‐Interferon. American Journal of Hematology. 2024. doi:10.1002/ajh.27311
BibTeX
@article{Song2024,
author = {Song, Jihyun and Lanikova, Lucie and Kim, Soo Jin and Papadopoulos, Nicolas and Meznarich, Jessica and Constantinescu, Stefan N and Parsegov, Brynn and Prchal, Jaroslav F and Prchal, Josef T},
title = {Novel germline JAK2 R715T mutation causing PV ‐like erythrocytosis in 3 generations. Amelioration by Ropeg‐Interferon},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.27311}
}
EUVIMED